Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9999747 | 1.00 | CYP1A2 (0.34) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13464035 | 1.00 | CYP1A2 (0.34) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13463951 | 0.95 | CYP1A2 (0.39) | CYP1A2HTTLMNAMAPK1 | |
| SCHEMBL9979801 | 0.95 | CYP1A2 (0.39) | CYP1A2HTTLMNAMAPK1 | |
| SCHEMBL13463953 | 0.95 | CYP1A2 (0.37) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13464034 | 0.94 | CYP1A2 (0.40) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL9999744 | 0.92 | CYP1A2 (0.35) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13464012 | 0.92 | CYP1A2 (0.35) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13463952 | 0.92 | CYP1A2 (0.35) | CYP1A2PKMHTTMEN1KMT2A | |
| SCHEMBL13464015 | 0.91 | CYP1A2 (0.42) | CYP1A2HTTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340328-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-11667845-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20180223187-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| WO-2017102053-A2 | CINNAMIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| EP-2628779-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2993216-A1 | COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-20150275088-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150275088-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| WO-2012079676-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667845-B2 | Liquid crystalline medium | NEFM, CCNI, MYT1 | CYP1A2 295/4885PKM 1261/4885HTT 759/4885 |
| US-20150275088-A1 | LIQUID-CRYSTALLINE MEDIUM | SOST, FES, VIM | CYP1A2 2987/4885PKM 736/4885HTT 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.